EUCTR2004-004024-12-DE进行中（未招募）1 期
Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma - STOMOX II
Technical University of Munich0 个研究点目标入组 0 人开始时间: 2005年2月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •histologically confirmed gastro-oesophageal adenocarcinoma
- •advanced disease (locally irresectable or metatstatic)
- •no systemic pretreatment, one neoadjuvant or adjuvant chemotherapy is acceptable (>6 month)
- •at least one unidimensional measurable cancer manifestation (>/= 1cm)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Second malignancy
- •Cardiac insufficiency, untreated ischemic heart disease
- •Uncontrolled Infection
- •Uncontrolled diabetes mellitus
研究者
相似试验
进行中（未招募）
1 期
Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma - STOMOX IIadvanced gastro-oesophageal adenocarcinomaEUCTR2004-004024-12-ATTechnical University of Munich
Unknown
2 期
EGFR Monoclonal Antibody for Advanced Gastric CancerCetuximabNimotuzumabGastric CancerNCT04136600Shanghai Changzheng Hospital100
进行中（未招募）
不适用
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
不适用
Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapyPatients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy.MedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-002811-98-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE100
进行中（未招募）
不适用
Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer - RAGEEUCTR2009-017943-32-BEAntwerp University Hospital25